The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study
Abstract
Parkinson's disease is a heterogeneous disorder with multiple factors contributing to disease initiation and progression. Using serial, multi-tracer positron emission tomography imaging, we studied a cohort of 78 subjects with sporadic Parkinson's disease to understand the disease course better. Subjects were scanned with radiotracers of presynaptic dopaminergic integrity at baseline and again after 4 and 8 years of follow-up. Non-linear multivariate regression analyses, using random effects, of the form BP(ND)(t) or K(occ)(t) = a*e((-)(bt)(-d)(A) + c, where BP(ND) = tracer binding potential (nondispaceable), K(OCC) = tracer uptake constant a, b, c and d are regression parameters, t is the symptom duration and A is the age at onset, were utilized to model the longitudinal progression of radiotracer binding/uptake. We found that the initial tracer binding/uptake was significantly different in anterior versus posterior striatal subregions, indicating that the degree of denervation at disease onset was different between regions. However, the relative rate of decline in tracer binding/uptake was similar between the striatal subregions. While an antero-posterior gradient of severity was maintained for dopamine synthesis, storage and reuptake, the asymmetry between the more and less affected striatum became less prominent over the disease course. Our study suggests that the mechanisms underlying Parkinson's disease initiation and progression are probably different. Whereas factors responsible for disease initiation affect striatal subregions differently, those factors contributing to disease progression affect all striatal subregions to a similar degree and may therefore reflect non-specific mechanisms such as oxidative stress, inflammation or excitotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722
Patlak, C. S., & Blasberg, R. G. (1985) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1985.87 · Cited by 1,673
Molecular Pathways of Neurodegeneration in Parkinson's Disease
Dawson, T. M., & Dawson, V. L. (2003) · Science · doi:10.1126/science.1087753 · Cited by 1,663
MRI-PET Registration with Automated Algorithm
Woods, R. P., Mazziotta, J. C., & R. Cherry, A. S. (1993) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199307000-00004 · Cited by 1,617
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514
Aging, energy, and oxidative stress in neurodegenerative diseases
Beal, M. F. (1995) · Annals of Neurology · doi:10.1002/ana.410380304 · Cited by 1,440
Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050
Kraytsberg, Y., Kudryavtseva, E., McKee, A. C., Geula, C., Kowall, N. W., & Khrapko, K. (2006) · Nature Genetics · doi:10.1038/ng1778 · Cited by 887
Criteria for diagnosing Parkinson's disease
Calne, D. B., Snow, B. J., & Lee, C. (1992) · Annals of Neurology · doi:10.1002/ana.410320721 · Cited by 628
Self-citationBrooks, D. J., Ibanez, V., Sawle, G. V., Quinn, N., Lees, A. J., Mathias, C. J., Bannister, R., Marsden, C. D., & Frackowiak, R. S. J. (1990) · Annals of Neurology · doi:10.1002/ana.410280412 · Cited by 626
Lee, C. S., Samii, A., Sossi, V., Ruth, T. J., Schulzer, M., Holden, J. E., Wudel, J., Pal, P. K., De La Fuente-Fernandez, R., Calne, D. B., et al. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200004)47:4<493::aid-ana13>3.0.co;2-4 · Cited by 580
Self-citationRate of cell death in parkinsonism indicates active neuropathological process
McGeer, P. L., Itagaki, S., Akiyama, H., & McGeer, E. G. (1988) · Annals of Neurology · doi:10.1002/ana.410240415 · Cited by 556
Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach
Lewis, S. J. G. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.033530 · Cited by 551
Jenner, P., Dexter, D. T., Sian, J., Schapira, A. H. V., Marsden, C. D., & The Royal Kings And Queens Parkinson's Disease Research Group (1992) · Annals of Neurology · doi:10.1002/ana.410320714 · Cited by 544
AETIOLOGY OF PARKINSON'S DISEASE
Calne, D., & William Langston, J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90802-4 · Cited by 469
Self-citationMcGeer, P. L., Schwab, C., Parent, A., & Doudet, D. (2003) · Annals of Neurology · doi:10.1002/ana.10728 · Cited by 400
Apoptosis in Parkinson's disease: Signals for neuronal degradation
Tatton, W. G., Chalmers-Redman, R., Brown, D., & Tatton, N. (2003) · Annals of Neurology · doi:10.1002/ana.10489 · Cited by 397
Changes in network activity with the progression of Parkinson's disease
Huang, C., Tang, C., Feigin, A., Lesser, M., Ma, Y., Pourfar, M., Dhawan, V., & Eidelberg, D. (2007) · Brain · doi:10.1093/brain/awm086 · Cited by 395
The role of radiotracer imaging in Parkinson disease
Ravina, B., Eidelberg, D., Ahlskog, J. E., Albin, R. L., Brooks, D. J., Carbon, M., Dhawan, V., Feigin, A., Fahn, S., Guttman, M., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000149403.14458.7f · Cited by 374
Self-citationAn [18F]dopa–PET and clinical study of the rate of progression in Parkinson’s disease
Morrish, P. K., Sawle, G. V., & Brooks, D. J. (1996) · Brain · doi:10.1093/brain/119.2.585 · Cited by 366
Protein Misfolding, Amyloid Formation, and Neurodegeneration
Muchowski, P. J. (2002) · Neuron · doi:10.1016/s0896-6273(02)00761-4 · Cited by 308
Hilker, R., Schweitzer, K., Coburger, S., Ghaemi, M., Weisenbach, S., Jacobs, A. H., Rudolf, J., Herholz, K., & Heiss, W.-D. (2005) · Archives of Neurology · doi:10.1001/archneur.62.3.378 · Cited by 293
Nigrostriatal function in humans studied with positron emission tomography
Martin, W. R. W., Palmer, M. R., Patlak, C. S., & Calne, D. B. (1989) · Annals of Neurology · doi:10.1002/ana.410260407 · Cited by 282
Self-citationThe Relationship of Parkinson Disease With Aging
Levy, G. (2007) · Archives of Neurology · doi:10.1001/archneur.64.9.1242 · Cited by 251
Mitochondria in the etiology and pathogenesis of parkinson's disease
Schapira, A. H. V., Gu, M., Taanman, J. ‐., Tabrizi, S. J., Seaton, T., Cleeter, M., & Cooper, J. M. (1998) · Annals of Neurology · doi:10.1002/ana.410440714 · Cited by 238
Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease
BROOKS, D. (2003) · Experimental Neurology · doi:10.1016/j.expneurol.2003.08.008 · Cited by 233
CLINICAL RELEVANCE OF SPECIFIC IgG ANTIBODIES TO CARDIOLIPIN
Faux, J. A., Byron, M. A., & Chapel, H. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92069-2 · Cited by 165
Influence of l -dopa and pramipexole on striatal dopamine transporter in early PD
Guttman, M., Stewart, D. E., Hussey, D., Wilson, A., Houle, S., & Kish, S. J. (2001) · Neurology · doi:10.1212/wnl.56.11.1559 · Cited by 151
Clinical observations on the rate of progression of idiopathic parkinsonism
Lee, C. S., Schulzer, M., Mak, E., Snow, B. J., Tsui, J. K. C., Clane, S., Hammerstad, J. P., & Clane, D. B. (1994) · Brain · doi:10.1093/brain/117.3.501 · Cited by 147
Self-citationProgression of Hoehn and Yahr stages in parkinsonian disorders: A clinicopathologic study
Müller, J. W., Wenning, G. K., Jellinger, K. A., McKee, A. C., Poewe, W. H., & Litvan, I. (2000) · Neurology · doi:10.1212/wnl.55.6.888 · Cited by 120
The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease
Ahlskog, J. E., Uitti, R. J., O’Connor, M. K., Maraganore, D. M., Matsumoto, J. Y., Stark, K. F., Turk, M. F., & Burnett, O. L. (1999) · Movement Disorders · doi:10.1002/1531-8257(199911)14:6<940::aid-mds1005>3.0.co;2-y · Cited by 105
Relationship of Striatal Dopamine Synthesis Capacity to Age and Cognition
Braskie, M. N., Wilcox, C. E., Landau, S. M., O’Neil, J. P., Baker, S. L., Madison, C. M., Kluth, J. T., & Jagust, W. J. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.3729-08.2008 · Cited by 102
A mathematical model of pathogenesis in idiopathic parkinsonism
Schulzer, M., Lee, C. S., Mak, E., Vingerhoets, F. J. G., & Calne, D. B. (1994) · Brain · doi:10.1093/brain/117.3.509 · Cited by 57
Self-citationLee, C. S., Schulzer, M., de la Fuente‐Fernández, R., Mak, E., Kuramoto, L., Sossi, V., Ruth, T. J., Calne, D. B., & Stoessl, A. J. (2004) · Archives of Neurology · doi:10.1001/archneur.61.12.1920 · Cited by 54
Self-citationParkinson's disease: in vivo assessment of disease progression using positron emission tomography
Au, W. L., Adams, J. R., Troiano, A. R., & Stoessl, A. J. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.09.028 · Cited by 49
Self-citationLate Progression of Post-Encephalitic Parkinson's Syndrome
Calne, D. B., & Lees, A. J. (1988) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100027499 · Cited by 46
Self-citationParkinson's disease is not one disease
Calne, D. B. (2000) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(00)00042-0 · Cited by 46
Self-citationNon-linear random effects model for multivariate responses with missing data
Marshall, G., de la Cruz, R., Barón, A. E., Rutledge, J. H., & Zerbe, G. O. (2005) · Statistics in Medicine · doi:10.1002/sim.2361 · Cited by 38
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Cited by
Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease
Redgrave, P., Rodriguez, M., Smith, Y., Rodriguez-Oroz, M. C., Lehericy, S., Bergman, H., Agid, Y., DeLong, M. R., & Obeso, J. A. (2010) · Nature reviews. Neuroscience · doi:10.1038/nrn2915 · Cited by 1,134
“In most cases, however, it is unclear whether these deficits reflect a partial, disease-related loss of dopaminergic input to associative territories of the striatu”
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
“in early (or presumably presymptomatic) phases of disease.(112) Reverse extrapolation of the exponential defining this pattern of decline suggests that vesicular monoamine transporter type 2 binding declines first (more than 15 years prior to disease onset), followed by a decline in DAT binding (some 10-15 years prior…”
Self-citationMissing pieces in the Parkinson's disease puzzle
Obeso, J. A., Rodriguez-Oroz, M. C., Goetz, C. G., Marin, C., Kordower, J. H., Rodriguez, M., Hirsch, E. C., Farrer, M., Schapira, A. H. V., & Halliday, G. (2010) · Nature Medicine · doi:10.1038/nm.2165 · Cited by 734
Glia: Initiators and progressors of pathology in Parkinson's disease
Halliday, G. M., & Stevens, C. H. (2011) · Movement Disorders · doi:10.1002/mds.23455 · Cited by 424
Metadata
- Authors
- Nandhagopal, R., Kuramoto, L., Schulzer, M., Mak, E., Cragg, J., Lee, C. S., McKenzie, J., McCormick, S., Samii, A., Troiano, A., Ruth, T. J., Sossi, V., de la Fuente-Fernandez, R., Calne, D. B., & Stoessl, A. J.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08-18
- Volume
- 132
- Issue
- 11
- Pages
- 2970-2979
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2129167248
- Cited by
- 259
- References
- 43
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.